139 related articles for article (PubMed ID: 14500410)
1. Immunomodulatory drugs for psoriasis.
Boehncke WH
BMJ; 2003 Sep; 327(7416):634-5. PubMed ID: 14500410
[No Abstract] [Full Text] [Related]
2. Immunologic targets in psoriasis.
Kupper TS
N Engl J Med; 2003 Nov; 349(21):1987-90. PubMed ID: 14627782
[No Abstract] [Full Text] [Related]
3. Anti-TNF-alpha therapy in childhood pustular psoriasis.
Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
[No Abstract] [Full Text] [Related]
4. Treatment of inflammatory dermatoses with novel biologic agents: a primer.
Nussbaum R; Krueger JG
Adv Dermatol; 2002; 18():45-89. PubMed ID: 12528402
[No Abstract] [Full Text] [Related]
5. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
Girolomoni G; Abeni D
Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
[No Abstract] [Full Text] [Related]
6. Biological agents and psoriatic epidermis: what are we ultimately targeting?
Heenen M; Simonart T
Dermatology; 2006; 212(4):321-3. PubMed ID: 16707880
[No Abstract] [Full Text] [Related]
7. Barriers to biologics.
Weinberg JM
Cutis; 2004 Sep; 74(3):164. PubMed ID: 15499757
[No Abstract] [Full Text] [Related]
8. Etanercept for the treatment of severe childhood psoriasis.
Papoutsaki M; Costanzo A; Mazzotta A; Gramiccia T; Soda R; Chimenti S
Br J Dermatol; 2006 Jan; 154(1):181-3. PubMed ID: 16403117
[No Abstract] [Full Text] [Related]
9. The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients.
Young MS; Horn EJ; Cather JC
Expert Rev Clin Immunol; 2011 Jan; 7(1):9-13. PubMed ID: 21162644
[TBL] [Abstract][Full Text] [Related]
10. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab vs. etanercept in psoriasis.
Downs AM
Clin Exp Dermatol; 2007 Sep; 32(5):593. PubMed ID: 17692064
[No Abstract] [Full Text] [Related]
12. Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
[No Abstract] [Full Text] [Related]
13. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
Farnsworth NN; George SJ; Hsu S
Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
[No Abstract] [Full Text] [Related]
14. New biologic therapies for psoriatic disease.
Bohjanen KA; Prawer SE
Minn Med; 2004 Mar; 87(3):34-6. PubMed ID: 15080292
[TBL] [Abstract][Full Text] [Related]
15. Switching biologics for psoriasis.
Ormerod AD
Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
[No Abstract] [Full Text] [Related]
16. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
Paul C; Solignac M
Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
[No Abstract] [Full Text] [Related]
17. [Risks and side effect reactions during therapy with TNF-alpha blockers. An immunologic analysis].
Berg PA
Dtsch Med Wochenschr; 2004 Jul; 129(30):1631-4. PubMed ID: 15257503
[No Abstract] [Full Text] [Related]
18. Systemic therapies for psoriasis: understanding current and newly emerging therapies.
Sobell JM; Hallas SJ
Semin Cutan Med Surg; 2003 Sep; 22(3):187-95. PubMed ID: 14649586
[TBL] [Abstract][Full Text] [Related]
19. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
Bachelez H; Battistella M
Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
[No Abstract] [Full Text] [Related]
20. [Biological therapeutic agents and patient autonomy in dermatologic therapy. The Danish Society of Dermatology].
Bygum A; Jemec GB
Ugeskr Laeger; 2004 Mar; 166(12):1105. PubMed ID: 15067764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
